SCHEMBL2748906

SCHEMBL2748906

CN(C)CCNC(=O)c1cccc(-c2cnc(N)c(-c3nc4ccccc4s3)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 1/20 0.62
PRKD1 Q15139 1/20 0.62
PRKD2 Q9BZL6 1/20 0.62
FYN P06241 8/20 0.54
MAP4K4 O95819 1/20 0.54
CAMK2D Q13557 4/20 0.49
CDK1 P06493 1/20 0.46
CDK2 P24941 1/20 0.46
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
GRK5 P34947 1/20 0.46
CHEK2 O96017 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HPGD P15428 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750800 0.92 PRKD3 (0.54) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL2748397 0.91 PRKD3 (0.53) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL2749016 0.90 FYN (0.51) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL2748849 0.86 CDK8 (0.50) FYNMAP4K4CDK1CDK2MKNK1
SCHEMBL2750376 0.86 ATR (0.54) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1678628 0.85 PRKD3 (0.63) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL1679117 0.84 PRKD3 (0.71) PRKD3PRKD1PRKD2FYNMAP4K4
SCHEMBL2748893 0.84 MKNK2 (0.64) FYNMAP4K4CDK1CDK2MKNK1
SCHEMBL2748293 0.83 GRK5 (0.53) FYNMAP4K4GRK5RAB9AHPGD
SCHEMBL1679743 0.82 PRKD3 (0.74) PRKD3PRKD1PRKD2FYNMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 PRKD3 199/4885PRKD1 117/4885PRKD2 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.